BioSpace News Archive

Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended June 30, 2021, and provided an update on the Company’s clinical development programs and regulatory and commercial outlook for the rest of the year.

ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity 41st Annual Growth Conference on Wednesday, August 11 at 5:00 p.m. ET.

Resonant Inc., today announced that management will present at the Oppenheimer 24 th Annual Virtual Technology, Internet & Communications Conference taking place August 9-11, 2021.

Oyster Point Pharma, Inc. today announced that it will report second quarter 2021 financial results on Thursday, August 5, 2021, after the market close.

Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, announced today participation in fireside chats at the following virtual conferences: BTIG Virtual Biotechnology Conference: August 9 at 1:30 p.m. ET Canaccord Genuity 41st Annual Growth Conference: August 11 at 9:00 a.m. ET

Rgenta Therapeutics, Inc., announced today a strategic R&D collaboration with H. Lundbeck A/S aimed at the discovery of small molecules targeting RNA regulation and splicing of disease-causing genes for neurological disorders.

Cerus Corporation (Nasdaq: CERS) today announced the appointment of Ann Lucena, CEO of San Ramon Regional Medical Center (SRRMC), to its Board of Directors.

Composition of Matter Patent Covers More than 80 Novel Compounds [04-August-2021] MELBOURNE, Australia , Aug. 4, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced the United States Patent and Tr

OliX Pharmaceuticals, Inc. today presented preclinical data on OLX702A, an investigational therapeutic for the treatment of nonalcoholic steatohepatitis (NASH), at the 48th Korean Academy of Science and Technology (KAST) International Symposium.

As new therapeutic drug treatments become available to help slow the progression of kidney disease, it is important to ensure that patients have access to, and can afford, these innovations that improve clinical outcomes.